Precision BioSciences Says Safety Board Clears Further Dosing In Phase 1/2 PBGENE-DMD Duchenne Trial After No Serious Adverse Events In First Patient
Share
Why It Matters
Precision BioSciences got permission to treat more patients in a medical trial. The first patient did not have serious side effects, which is a good early sign.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.